Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage 0 bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-13 of 13 for your search:
Start Over
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.7, NCI-2015-01830, BOND 2 version 3.4, BOND 2 version 3.5, NCT02365818
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB4-845-02-IIIA, NCI-2015-01369, NCT02449239
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SPI-EOQ-13-305, NCI-2016-00340, NCT02563561
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: BC001, NCI-2015-01102, 1R42CA171552-01, NCT02009332
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: WO29635, NCI-2016-01018, NCT02792192
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Dovitinib Lactate in Treating Patients With Refractory or Stage 0-I Bladder Cancer With FGFR3 Mutations or Overexpression
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU12-157, NCI-2013-00610, 1211009949, CTKI258AUS17T, NCT01732107
BCG Solution in Treating Patients with Non-muscle Invasive Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-174, NCI-2014-02528, NCT02281383
Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-057, NCI-2016-00312, 2014-004026-17, NCT02625961
Cabazitaxel, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with BCG solution-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM8506, NCI-2015-00757, NCT02202772
BGJ398 in Treating Patients with Non-Muscle-Invasive Urothelial Cancer of the Bladder
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-090, NCI-2016-00119, NCT02657486
Observation or Immediate Surgery in Reducing Complications in Patients with Low Risk Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 50 and over
Trial IDs: VICC URO 15139, NCI-2016-00677, NCT02700724
Start Over